LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New, Enzyme-Free Glucose Monitoring Sensor Solution Could Find Applications in Range of POC Diagnostics

By LabMedica International staff writers
Posted on 03 Feb 2022
Image: Enzyme-Free Sensor (Photo courtesy of Integrated Graphene)
Image: Enzyme-Free Sensor (Photo courtesy of Integrated Graphene)

Researchers have developed a new glucose sensor that is cheaper and more robust than current systems, opening up the possibility of taking the underlying applied methodology to a vast range of similar point-of-care diagnostics.

Researchers at the University of Bath (Bath, UK) working in collaboration with industrial partner, Integrated Graphene (Stirling, UK) have developed a new sensing technique based on graphene foam for the detection of glucose levels in the blood. Since it is a chemical sensor instead of being enzyme-based, the new technology is robust, has a long shelf-life and can be tuned to detect lower glucose concentrations than current systems.

Many current biosensors use enzymes that bind glucose and produce an electric current proportional to the concentration of glucose in the blood sample. The new technique uses a chemical sensor, which is more robust and is not affected by high temperatures or changes in pH. Furthermore, it has the potential to accurately detect a wider range of glucose concentrations above and below current biosensor ranges, which may be useful in neonatal glucose sensing.

The new sensor is based on the chemical boronic acid, which is attached to a graphene foam surface. An electroactive polymer layer is added on top and binds to the boronic acid. When glucose is present, it competitively binds to the boronic acid, displacing the polymer. The sensor produces an electric current proportional to how much polymer is displaced, meaning that the concentration of glucose in the sample can be accurately measured. The researchers anticipate the sensor will expand the scope of boronic acid - based glucose sensing. Their sensor is based upon electrochemical methods rather than fluorescence, thereby enabling new boronic acid – based glucose sensing approaches.

“We’re excited by our results as this is the first time this approach has been used for glucose sensing,” said Professor Tony James, who is a Royal Society Wolfson Research Merit Award holder at the University of Bath’s Department of Chemistry and helped supervise the project. “We are still in the early stages of optimizing sensitivity and reproducibility but hope this new technology could be used in a wide range of applications, from medical sensing to food production. It could also be adapted to sense other molecules or for use in continuous flow systems.”

“Now, with this project alongside the University of Bath, we are beginning to see some of that potential being realized to create a more cost-effective and therefore accessible platform by using a new, enzyme-free glucose monitoring sensor solution,” said Dr. Marco Caffio, Co-Founder and CSO of Integrated Graphene, said: “When we started Integrated Graphene. “Now that we have proved this technique, it opens up the opportunity to take the underlying applied methodology to a vast range of similar point-of-care diagnostics that could profit from associated benefits such as reduced cost and enhanced shelf-life.”

Related Links:
University of Bath 
Integrated Graphene 

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more